Roche buys Lonza’s Singapore biologics plant
Basel-headquartered Roche has paid fellow Swiss firm Lonza $290m (€203m) for its Singapore biologics plant in a bid to secure long-term manufacturing capacity for biotech cancer drugs.
Novartis’ former CEO joining Amylin’s board and an appointment at OctoPlus – People on the move
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including Novartis’ former CEO joining Amylin’s board and an appointment at OctoPlus.
Durect and King sign long-term Remoxy excipient supply deal
Chemicals firm Durect will supply drugmaker King Pharmaceuticals with two excipients used in the manufacture of the candidate anti-abuse painkiller Remoxy in an agreement signed last week.
BASF hikes carboxylic acid prices in Europe
German chemicals manufacturer BASF has raised the price of two of its range of carboxylic acids, as part of a round of increases.
Silence collaborating on AtuRNAi drug delivery tech
Dainippon Sumitomo Pharma has entered into a collaboration to develop Silence Therapeutics’ AtuRNAi delivery technology which improves stability, cut manufacturing costs and increase stability.
Phone-based anti-counterfeiting proposed for developing world
Researchers have presented a low cost track and trace and authentication system, which they believe could be implemented immediately, to combat counterfeiting in the developing world.
Europe leads US in R&D productivity, says Health Affairs
Europe is pulling ahead of the US in research productivity, according to a controversial new study by Washington public policy think tank Health Affairs.
Pfizer inaugurates new $214m Swedish biotech plant
Pfizer’s new $214.8 million (€150m) biotechnology facility in Strangnas, Sweden was inaugurated yesterday, securing the country’s future in the company’s manufacturing network according to global manufacturing president Natale Ricciardi.
Mantecorp installs tech to cut energy use
Mantecorp is using the Control and Communication Link (CC-Link) open fieldbus network to improve the environmental credentials of its facility in Rio de Janeiro, Brazil.
Protein therapeutics worth $77bn by 2011, says RNCOS
The global protein therapeutics market will be worth $77bn by 2011 with biogenerics playing an increasingly important role, according to a new survey by industry analysts RNCOS.
GSK reports theft of 25,600 Advair inhalers
UK drug major GSK says that two lots of its respiratory drug Advair Diskus have been stolen from a distribution facility in Richmond, Virginia in the US.
Cambrex’ Milan API plant gets FDA warning
US chemicals maker Cambrex will hope an FDA warning letter concerning its Italian manufacturing plant will not increase the pressure on its generic active pharmaceutical ingredients (API) business.
Appointments at Sutro Biopharma Lundbeck and AmerisourceBergen – People on the move
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at Sutro Biopharma Lundbeck and AmerisourceBergen.
Warner Chilcott may pay $3bn for P&G drug unit
Woman’s healthcare and dermatology group Warner Chilcott will unveil plans to buy P&G’s prescription drug division for $3bn (€2.1bn) according to a number of media reports.
Will Lonza's $460m Patheon offer trigger bidding war?
Canadian contractor Patheon has welcomed the $460m (€321m) takeover offer from Switzerland's Lonza that could, according to some observers, spark a bidding war with rival suitor, US group JLL Patheon Holdings.